Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study

The International Journal of Artificial Organs
Elettra C PoliAntoine G Schneider

Abstract

Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infections are rare but associated with very high mortality rates. We report the case of a 14-year-old patient with Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infection and Influenza B pneumonia requiring veno-arterial extra-corporeal membrane oxygenator for refractory shock. In the absence of response to conventional therapy, we have inserted a Cytosorb® cartridge within the extra-corporeal membrane oxygenator circuit. A spectacular decrease in vasopressor requirements followed. Since clindamycin, a key component of Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus treatment, might be removed by Cytosorb® hemoadsorption, we have performed serial plasma concentrations measurements of the drug. Based on these measurements, we were able to develop a pharmacokinetic model incorporating variable plasma clearance. Patient's exposure was estimated before, during and after Cytosorb® hemoadsorption. According to this model, Cytosorb® hemoadsorption did not seem to result in significant clindamycin removal. Cytosorb® hemoadsorption during Panton-Valentine leucocidin producing methicilli...Continue Reading

References

Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Sep 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robin L TrotmanWilliam L Salzer
Mar 17, 2010·Proceedings of the National Academy of Sciences of the United States of America·Binh An DiepHenry F Chambers
Jun 2, 2015·The Journal of Infection·Claire E Turner, Shiranee Sriskandan
Jul 21, 2016·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·N J LeesA F Popov
Jan 28, 2017·Journal of Intensive Care·Sascha DavidJan T Kielstein
Feb 1, 2017·Antimicrobial Agents and Chemotherapy·Michael J SmithUNKNOWN Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee
May 8, 2018·Intensive Care Medicine Experimental·Benjamin MalardJohn A Kellum
Nov 18, 2018·Intensive Care Medicine·Elettra C PoliAntoine G Schneider

❮ Previous
Next ❯

Citations

Apr 29, 2020·The International Journal of Artificial Organs·Thomas DimskiDetlef Kindgen-Milles
May 16, 2019·Annals of Intensive Care·Patrick M HonoreLui G Forni
Mar 10, 2021·Artificial Organs·Anna Mara ScandroglioFederico Pappalardo
May 20, 2021·Scientific Reports·Antoine G SchneiderDetlef Kindgen-Milles

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
amputation

Software Mentioned

Solver
Excel

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

BMJ : British Medical Journal
Jerome Etienne, Oana Dumitrescu
The Lancet Infectious Diseases
Binh An DiepFrançois Vandenesch
Intensive Care Medicine
Elettra C PoliAntoine G Schneider
© 2022 Meta ULC. All rights reserved